Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-OA PAIN: orforglipron in overweight or obesity with knee osteoarthritis
CTR20254312Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Oct 2025; status: active.
02
Drugs
orforglipron
03
Conditions
obesityOverweightosteoarthritis (OA)
Beyond the preview
Go deeper on CTR20254312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254312.